{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T17:49:59Z","timestamp":1740160199151,"version":"3.37.3"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2020,10,3]],"date-time":"2020-10-03T00:00:00Z","timestamp":1601683200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,10,3]],"date-time":"2020-10-03T00:00:00Z","timestamp":1601683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Novo Nordisk A\/S"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetes Ther"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s13300-020-00936-5","type":"journal-article","created":{"date-parts":[[2020,10,3]],"date-time":"2020-10-03T16:02:24Z","timestamp":1601740944000},"page":"2909-2920","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Reduced Rates of Hypoglycemia in Type 1 or Type 2 Diabetes After Switching to Insulin Degludec: Results from the Italian Cohort of the ReFLeCT Study"],"prefix":"10.1007","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6510-2097","authenticated-orcid":false,"given":"Gian Paolo","family":"Fadini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla","family":"Giordano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Salvi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Nicolucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"The REFLECT Italian Study Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,10,3]]},"reference":[{"key":"936_CR1","doi-asserted-by":"publisher","first-page":"3169","DOI":"10.2337\/db08-1084","volume":"57","author":"PE Cryer","year":"2008","unstructured":"Cryer PE. The barrier of hypoglycemia in diabetes. Diabetes. 2008;57:3169\u201376.","journal-title":"Diabetes"},{"key":"936_CR2","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.2337\/diacare.28.5.1245","volume":"28","author":"Workgroup on Hypoglycemia, American Diabetes Association","year":"2005","unstructured":"Workgroup on Hypoglycemia, American Diabetes Association. Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care. 2005;28:1245\u20139.","journal-title":"Diabetes Care"},{"key":"936_CR3","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.diabres.2017.05.004","volume":"130","author":"K Khunti","year":"2017","unstructured":"Khunti K, Alsifri S, Aronson R, et al. Impact of hypoglycaemia on patient reported outcomes from a global, 24-country study of 27,585 people with type 1 and insulin treated type 2 diabetes. Diabetes Res Clin Pract. 2017;130:121\u20139.","journal-title":"Diabetes Res Clin Pract"},{"key":"936_CR4","unstructured":"Novo Nordisk A\/S. Tresiba (Insulin Degludec) summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/tresiba-epar-product-information_en.pdf. Accessed Dec 2019."},{"key":"936_CR5","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1111\/j.1463-1326.2012.01627.x","volume":"14","author":"T Heise","year":"2012","unstructured":"Heise T, Hermanski L, Nosek L, Feldman A, Rasmussen S, Haahr H. Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabetes Obes Metab. 2012;14:859\u201364.","journal-title":"Diabetes Obes Metab"},{"key":"936_CR6","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1111\/dom.12938","volume":"19","author":"T Heise","year":"2017","unstructured":"Heise T, Norskov M, Nosek L, Kaplan K, Famulla S, Haahr HL. Insulin degludec: lower day-to day and within-day variability in pharmacodynamic response compared with insulin glargine 300 U\/mL in type 1 diabetes. Diabetes Obes Metab. 2017;19:1032\u20139.","journal-title":"Diabetes Obes Metab"},{"key":"936_CR7","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1111\/dom.12032","volume":"15","author":"RE Ratner","year":"2013","unstructured":"Ratner RE, Gough SC, Mathieu C, et al. Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials. Diabetes Obes Metab. 2013;15:175\u201384.","journal-title":"Diabetes Obes Metab"},{"key":"936_CR8","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1001\/jama.2017.7115","volume":"318","author":"W Lane","year":"2017","unstructured":"Lane W, Bailey TS, Gerety G, et al. Effect of insulin degludec vs insulin glargine U100 on hypoglycemia in patients with type 1 diabetes: the SWITCH 1 randomized clinical trial. JAMA. 2017;318:33\u201344.","journal-title":"JAMA"},{"key":"936_CR9","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1001\/jama.2017.7117","volume":"318","author":"C Wysham","year":"2017","unstructured":"Wysham C, Bhargava A, Chaykin L, et al. Effect of insulin degludec vs insulin glargine U100 on hypoglycemia in patients with type 2 diabetes: the SWITCH 2 randomized clinical trial. JAMA. 2017;318:45\u201356.","journal-title":"JAMA"},{"key":"936_CR10","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1056\/NEJMoa1615692","volume":"377","author":"SP Marso","year":"2017","unstructured":"Marso SP, McGuire DK, Zinman B, et al. Efficacy and safety of degludec versus glargine in type 2 diabetes. N Engl J Med. 2017;377:723\u201332.","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"936_CR11","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/S0168-8227(10)70002-4","volume":"88","author":"W Yang","year":"2010","unstructured":"Yang W, Zilov A, Soewondo P, Bech OM, Sekkal F, Home PD. Observational studies: going beyond the boundaries of randomized controlled trials. Diabetes Res Clin Pract. 2010;88(Suppl 1):S3\u20139.","journal-title":"Diabetes Res Clin Pract"},{"key":"936_CR12","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1056\/NEJMsb1609216","volume":"375","author":"RE Sherman","year":"2016","unstructured":"Sherman RE, Anderson SA, Dal Pan GJ, et al. Real-world evidence\u2014what is it and what can it tell us? N Engl J Med. 2016;375:2293\u20137.","journal-title":"N Engl J Med"},{"key":"936_CR13","doi-asserted-by":"publisher","first-page":"96","DOI":"10.3111\/13696998.2014.975234","volume":"18","author":"M Evans","year":"2015","unstructured":"Evans M, McEwan P, Foos V. Insulin degludec early clinical experience: does the promise from the clinical trials translate into clinical practice\u2014a case-based evaluation. J Med Econ. 2015;18:96\u2013105.","journal-title":"J Med Econ"},{"key":"936_CR14","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1111\/dom.13149","volume":"20","author":"T Siegmund","year":"2018","unstructured":"Siegmund T, Tentolouris N, Knudsen ST, et al. A European, multicentre, retrospective, non-interventional study (EU-TREAT) of the effectiveness of insulin degludec after switching basal insulin in a population with type 1 or type 2 diabetes. Diabetes Obes Metab. 2018;20:689\u201397.","journal-title":"Diabetes Obes Metab"},{"key":"936_CR15","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1185\/03007995.2015.1058252","volume":"31","author":"L Landstedt-Hallin","year":"2015","unstructured":"Landstedt-Hallin L. Changes in HbA1c, insulin dose and incidence of hypoglycemia in patients with type 1 diabetes after switching to insulin degludec in an outpatient setting: an observational study. Curr Med Res Opin. 2015;31:1487\u201393.","journal-title":"Curr Med Res Opin"},{"key":"936_CR16","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1016\/j.numecd.2016.08.002","volume":"26","author":"S Galasso","year":"2016","unstructured":"Galasso S, Facchinetti A, Bonora BM, et al. Switching from twice-daily glargine or detemir to once-daily degludec improves glucose control in type 1 diabetes. An observational study. Nutr Metab Cardiovasc Dis. 2016;26:1112\u20139.","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"936_CR17","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.diabres.2017.03.031","volume":"129","author":"B Bohn","year":"2017","unstructured":"Bohn B, Zimmermann A, Wagner C, et al. Real-life experience of patients starting insulin degludec. A multicenter analysis of 1064 subjects from the German\/Austrian DPV registry. Diabetes Res Clin Pract. 2017;129:52\u20138.","journal-title":"Diabetes Res Clin Pract"},{"key":"936_CR18","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s13300-017-0225-z","volume":"8","author":"K Kaku","year":"2017","unstructured":"Kaku K, Wolden ML, Hyllested-Winge J, Nortoft E. Insulin degludec in clinical practice: a review of japanese real-world data. Diabetes Ther. 2017;8:189\u201395.","journal-title":"Diabetes Ther"},{"key":"936_CR19","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.dsx.2016.01.013","volume":"10","author":"S Ghosal","year":"2016","unstructured":"Ghosal S, Sinha B, Gangopadhyay KK. Insulin glargine versus insulin degludec in patients failing on oral therapy in type 2 diabetes: a retrospective real world comparative data from India. Diabetes Metab Syndr. 2016;10:161\u20135.","journal-title":"Diabetes Metab Syndr"},{"key":"936_CR20","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1111\/jdi.12373","volume":"7","author":"K Kobuke","year":"2016","unstructured":"Kobuke K, Yoneda M, Nakanishi S, Ohno H, Maeda S, Egusa G. Efficacy and safety of insulin degludec in Japanese patients with type 1 and type 2 diabetes: 24-week results from the observational study in routine clinical practice. J Diabetes Investig. 2016;7:94\u20139.","journal-title":"J Diabetes Investig"},{"key":"936_CR21","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1507\/endocrj.EJ15-0245","volume":"63","author":"T Urakami","year":"2016","unstructured":"Urakami T, Kuwabara R, Aoki M, Okuno M, Suzuki J. Efficacy and safety of switching from insulin glargine to insulin degludec in young people with type 1 diabetes. Endocr J. 2016;63:159\u201367.","journal-title":"Endocr J"},{"key":"936_CR22","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s13340-016-0275-x","volume":"8","author":"J Suzuki","year":"2017","unstructured":"Suzuki J, Yamakawa T, Nagakura J, Shigematsu E, Kadonosono K, Terauchi Y. Efficacy of switching from insulin glargine to insulin degludec in patients with type 1 diabetes: a 16-week retrospective study. Diabetol Int. 2017;8:45\u201351.","journal-title":"Diabetol Int"},{"key":"936_CR23","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1111\/jdi.12496","volume":"7","author":"S Shimoda","year":"2016","unstructured":"Shimoda S, Sato M, Sekigami T, et al. A 1-year, prospective, observational study of Japanese outpatients with type 1 and type 2 diabetes switching from insulin glargine or detemir to insulin degludec in basal-bolus insulin therapy (Kumamoto Insulin Degludec Observational study). J Diabetes Investig. 2016;7:703\u201310.","journal-title":"J Diabetes Investig"},{"key":"936_CR24","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1111\/dom.13616","volume":"21","author":"J Tibaldi","year":"2018","unstructured":"Tibaldi J, Hadley-Brown M, Liebl A, et al. A comparative effectiveness study of degludec and insulin glargine 300 U\/mL in insulin-na\u00efve patients with type 2 diabetes. Diabetes Obes Metab. 2018;21:1001\u20139.","journal-title":"Diabetes Obes Metab"},{"key":"936_CR25","doi-asserted-by":"publisher","first-page":"5977","DOI":"10.1210\/jc.2019-01021","volume":"104","author":"GP Fadini","year":"2019","unstructured":"Fadini GP, Feher M, Hansen TK, et al. Switching to degludec from other basal insulins is associated with reduced hypoglycemia rates: a prospective study. J Clin Endocrinol Metab. 2019;104:5977\u201390.","journal-title":"J Clin Endocrinol Metab"},{"key":"936_CR26","unstructured":"Bradley C (editor). The Diabetes Treatment Satisfaction Questionnaire. DTSQ. In: Bradley C, editor. Handbook of psychology and diabetes: a guide to psychological measurement in diabetes research and practice. Chur: Harwood Academic Publishers; 1994. p. 111\u201332."},{"key":"936_CR27","volume-title":"User's manual for the SF-36 v2 health survey","author":"JE Ware","year":"2007","unstructured":"Ware JE, Kosinski M, Bjorner JB, Turner-Bowker DM, Maruish ME. User's manual for the SF-36 v2 health survey. Lincoln: QualityMetric; 2007."},{"key":"936_CR28","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","volume":"310","author":"World Medical Association","year":"2013","unstructured":"World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310:2191\u20134.","journal-title":"JAMA"},{"key":"936_CR29","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.2337\/dc12-2480","volume":"36","author":"ER Seaquist","year":"2013","unstructured":"Seaquist ER, Anderson J, Childs B, et al. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care. 2013;36:1384\u201395.","journal-title":"Diabetes Care"},{"key":"936_CR30","first-page":"582","volume":"41","author":"GR Norman","year":"2003","unstructured":"Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care. 2003;41:582\u201392.","journal-title":"Med Care"},{"key":"936_CR31","first-page":"344","volume":"5","author":"CB Giorda","year":"2014","unstructured":"Giorda CB, Ozzello A, Gentile S, et al. Incidence and correlates of hypoglycemia in type 2 diabetes. The HYPOS-1 study. J Diabetes Metab. 2014;5:344.","journal-title":"J Diabetes Metab"},{"key":"936_CR32","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1007\/s00592-015-0713-4","volume":"52","author":"CB Giorda","year":"2015","unstructured":"Giorda CB, Ozzello A, Gentile S, et al. Incidence and risk factors for severe and symptomatic hypoglycemia in type 1 diabetes. Results of the HYPOS-1 study. Acta Diabetol. 2015;52:845\u201353.","journal-title":"Acta Diabetol"},{"key":"936_CR33","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1111\/dom.13614","volume":"21","author":"RS Holmes","year":"2019","unstructured":"Holmes RS, Crabtree E, McDonagh MS. Comparative effectiveness and harms of long-acting insulins for type 1 and type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab. 2019;21:984\u201392.","journal-title":"Diabetes Obes Metab"},{"key":"936_CR34","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.jpsychores.2015.08.010","volume":"79","author":"B Pintaudi","year":"2015","unstructured":"Pintaudi B, Lucisano G, Gentile S, et al. Correlates of diabetes-related distress in type 2 diabetes: findings from the benchmarking network for clinical and humanistic outcomes in diabetes (BENCH-D) study. J Psychosom Res. 2015;79:348\u201354.","journal-title":"J Psychosom Res"}],"container-title":["Diabetes Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-020-00936-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13300-020-00936-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-020-00936-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,4]],"date-time":"2021-10-04T19:31:48Z","timestamp":1633375908000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13300-020-00936-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,3]]},"references-count":34,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["936"],"URL":"https:\/\/doi.org\/10.1007\/s13300-020-00936-5","relation":{},"ISSN":["1869-6953","1869-6961"],"issn-type":[{"type":"print","value":"1869-6953"},{"type":"electronic","value":"1869-6961"}],"subject":[],"published":{"date-parts":[[2020,10,3]]},"assertion":[{"value":"27 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}